Business Wire

Industry-Leading Speakers Will Bring Melody to ‘Music City’ at Kinexions ‘23

23.5.2023 14:00:00 EEST | Business Wire | Press release

Share

New York Times best seller and popular podcast host Mel Robbins and supply chain thought leader and co-founder of Zero100 Kevin O’Marah will take the main stage during Kinexions ‘23, the conference for supply chain planners and innovators hosted by Kinaxis ®, Inc. (TSX:KXS). Held in Nashville on June 19-21, registration is now open for the in person and virtual event at www.kinexions.com.

On the heels of Kinaxis’ recent leadership position in the Gartner Magic Quadrant for Supply Chain Planning, this year’s event will welcome hundreds of global supply chain leaders to learn, share, and grow around the evolving discipline of supply chain, a topic that continues to ascend in prominence in the boardroom.

In addition to featured keynotes, the program will also comprise:

  • More than 1,000 minutes of content including peer-led sessions on topics related to supply chain innovation, leadership, and strategy from industry-leading companies, including General Motors, Mars, Seagen, Subaru, Trinity Rail, and Unilever.
  • 25 breakout sessions from Kinaxis experts and customers on current and future product innovation and hands-on demonstrations.
  • Networking and peer-to-peer learning opportunities by industry and job function.
  • More than 25 hours of free training and certification.
  • A Customer Appreciation Party and concert featuring music from emerging artists, alongside Grammy Award-winning Brothers Osborne.

“Nashville is home to some of the most talented musicians and it couldn’t be a more fitting host city for Kinexions,” said John Sicard, CEO of Kinaxis. “During these three days, our customer community will come together to share their stories of driving innovative change in supply chain – the work of harmonizing planning and execution – to unlock the agility that is necessary today.”

The event will kick off with a welcome reception and conclude with the party of the year at The Twelve Thirty Club, where attendees can sit back, relax, and celebrate each other and the industry’s progress to date.

Kinexions ’23 is made possible by its valued sponsors. Attendees will be able to connect with representatives from Platinum-level sponsors, Accenture, and Genpact, Gold-level sponsors, 4Flow, and CapGemini, Silver-level sponsors, IMTEK, LTI Mindtree, Scott Sheldon, Cognizant and Nextinfo and new for 2023 are our Cloud sponsors, Google Cloud and Microsoft, in-person to find out more about the ongoing innovation and their partnership with Kinaxis.

Finally, Kinaxis also partnered with Carbonzero to measure the carbon footprint of attendee travel, venue energy usage, hotel accommodations, and event-related landfill waste. Kinaxis will purchase third-party verified carbon offsets to mitigate the event’s climate impact.

To learn more about Kinaxis and its technology solutions, please visit www.kinaxis.com.

About Kinaxis Inc.

Everyday volatility and uncertainty demand quick action. Kinaxis® delivers the agility to make fast, confident decisions across integrated business planning and the digital supply chain. People can plan better, live better and change the world. Trusted by innovative brands, we combine human intelligence with AI and concurrent planning to help companies plan for any future, monitor risks and opportunities and respond at the pace of change. Powered by an extensible, cloud-based platform, Kinaxis delivers industry-proven applications so everyone can know sooner, act faster and remove waste. For more Kinaxis news, visit Kinaxis.com or follow us on LinkedIn or Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
289-552-4640

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye